A Phase 3 interventional study of Nipocalimab and Placebo in Myasthenia Gravis, sponsored by Janssen Research & Development, LLC. Recruiting at 112 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 144 studies in Myasthenia Gravis with a site in United States — 53 open to participants now, 73 under way, 25 of them phase 3. Myasthenia Gravis · United States.
Among the 144 studies in Myasthenia Gravis with a site in United States, this one is the 9th largest by planned enrollment of the 108 interventional ones that give a count, is one of 13 that started in 2021, is one of 45 in phase 3, reaches primary completion later than 1 of the 72 other live ones, and was the 65th registered.
331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.
Browse Myasthenia Gravis studies →53 of the 144 studies in Myasthenia Gravis with a site in United States are open now. Recruiting first, the newest first:
TG Therapeutics, Inc. · Sites in United States
Ages 18+
UCB Biopharma SRL · Sites in United States, China, France and 4 more countries
Ages 18+
George Washington University · Sites in United States
Ages 18+
Amgen · Sites in United States, Argentina, Brazil and 5 more countries
Ages 2–17
argenx · Sites in United States, Belgium, Greece and 4 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
144 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 38 · Phase 3 51 · Phase 4 3
First in 1995; this study’s year is marked. 13 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 199 is above the median of 44 across 218 interventional studies indexed under Myasthenia Gravis.
Median enrollment 56 across the 108 interventional studies, 226 across the 36 observational. Of the 64 that completed or were terminated, 41 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
96 of 144 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
Johnson & Johnson has 5 studies filed under Myasthenia Gravis — fewer than ten, so there is no comparison to draw.
18 of the studies in Myasthenia Gravis with a site in United States that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06607627Phase 3Alexion Pharmaceuticals, Inc.PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis | 2026-12-15 |
| NCT06799247Phase 3Cartesian TherapeuticsInvestigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis | 2026-12-30 |
| NCT04833894Phase 3argenxEvaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis | 2027-03 |
| NCT06456580Phase 3Vor BiopharmaA Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | 2027-03 |
| NCT06517758Phase 3Novartis PharmaceuticalsA Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. | 2027-04-30 |
Add all 18 to your calendar (.ics) → With an account.
Among the 144 studies in Myasthenia Gravis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to placebo in participants with generalized myasthenia gravis (gMG). The purpose of the subcutaneous substudy is to evaluate how well it works in the body (pharmacodynamic [PD]) when given as an injection under the skin (subcutaneous) compared to when given through a vein (intravenous) in participants with gMG.
The criteria were revised on the registry on Nov 5, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Double-blind Placebo-controlled Phase: Participants will receive nipocalimab intravenous (IV) infusions once every 2 weeks (q2w) up to 24 weeks during double-blind placebo-controlled phase. Open-label Extension (OLE) Phase: Participants who complete the double-blind placebo-controlled phase will enter the OLE phase and will have the option to continue to receive nipocalimab q2w IV infusion till study end or enter the nipocalimab SC substudy.
Drug: Nipocalimab
Double-blind Placebo-controlled Phase: Participants will receive matching placebo of nipocalimab IV infusion q2w up to 24 weeks during double-blind placebo-controlled phase.
Drug: Placebo
OLE Phase: Participants from Cohort 1 will receive nipocalimab subcutaneous liquid in vial (SC-LIV) qw until Week 8. Participants with gMG from Cohort 2 who have not received nipocalimab previously, will receive nipocalimab SC-LIV until Week 8. Participants who complete the 8-week treatment period will have the opportunity to continue receiving nipocalimab SC-LIV qw in the Long term extension (LTE) period.
Drug: Nipocalimab SC-LIV
Nipocalimab will be administered as an IV infusion.
Also known as: JNJ-80202135, M281
Matching placebo will be administered as an IV infusion.
Nipocalimab will be administered subcutaneously.
Double-blind (DB) Phase: Average Change From Baseline in Myasthenia Gravis - Activities of Daily Living (MG-ADL) Total Score Over Weeks 22, 23, and 24
Average change from baseline over multiple timepoints (Weeks 22, 23, and 24) was reported in this outcome measure. The MG-ADL provided a rapid assessment of the participant's MG symptom severity of eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, eyelid droop) rated on a 4-point scale ranging from 0 (normal) to 3 (severe). MG-ADL total score was sum of 8 individual items, which ranging from 0 to 24. A higher score indicated greater symptom severity. Baseline was defined as the average of the screening and Day 1 total scores.
Time frame: Baseline, Weeks 22, 23, and 24
Sub Study: Percent Change in Anti-AChR Autoantibody Titer From Pre-first Nipocalimab Dose on Day 1 up to Week 8 (Day 57)
Time frame: From pre-first nipocalimab dose on Day 1 up to Week 8 (Day 57)
Sub Study: Percent Change in Total IgG Levels From Pre-first Nipocalimab Dose on Day 1 up to Week 8 (Day 57)
Time frame: From pre-first nipocalimab dose on Day 1 up to Week 8 (Day 57)
DB Phase: Average Change From Baseline in Quantitative Myasthenia Gravis (QMG) Score Over Weeks 22 and 24
Time frame: Baseline, Weeks 22, and 24
DB Phase: Percentage of Participants Who Had Achieved at Least a 2-point Average Improvement From Baseline in Myasthenia Gravis - Activities of Daily Living (MG-ADL) Total Score Over Weeks 22, 23, and 24
Time frame: Weeks 22, 23, and 24
DB Phase: Percentage of Participants Who Had Achieved an Improvement of Greater Than or Equal to (>=) 2 Points in the Myasthenia Gravis - Activities of Daily Living (MG-ADL) Total Score at Week 1 and/or Week 2
Time frame: Weeks 1 and 2
DB Phase: Percentage of Participants Who Had an Improvement of >= 2 Points in the MG-ADL Total Score From Week 4 Through Week 24 With no More Than 2 Non-consecutive Excursions Allowed Between Weeks 6 Through 23
Time frame: From Week 4 up to Week 24
DB Phase: Percentage of Participants Who Had Achieved at Least a 50 Percent (%) Average Improvement From Baseline in the Myasthenia Gravis - Activities of Daily Living (MG-ADL) Total Score Over Weeks 22, 23, and 24
Time frame: Weeks 22, 23, and 24
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
Time frame: From start of treatment (DB phase Day 1) up to 4 years 9 months
Percentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
Time frame: From start of treatment (DB phase Day 1) up to 4 years 9 months
Percentage of Participants With AEs of Special Interest (AESIs)
Time frame: From start of treatment (DB phase Day 1) up to 4 years 9 months
Number of Participants With Change in Vital Signs
Time frame: From start of treatment (DB phase Day 1) up to 4 years 9 months
Number of Participants With Change in Clinical Laboratory Values
Time frame: From start of treatment (DB phase Day 1) up to 4 years 9 months
Number of Participants With Change From Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) Score
Time frame: From start of treatment (Day 1) up to 4 years 9 months
DB Phase: Percentage of Participants Who Had an Improvement of >= 3 Points in Quantitative Myasthenia Gravis (QMG) Score From Baseline, at Week 2 Through Week 24, With No More Than 2 Non-consecutive Excursions Allowed Between at Weeks 4 Through Week 22
Time frame: Baseline, Week 2 up to Week 24
DB Phase: Average Change From Baseline in the Fatigue Items of the Quality of Life in Neurological Disorders (Neuro-QoL) Fatigue Scale Total Score Over Weeks 22 and 24
Time frame: Baseline up to Weeks 22, and 24
DB Phase: Average Change From Baseline in the Revised Myasthenia Gravis Quality of Life (Revised) Instrument (MG-Qol15r) Score Over Weeks 22 And 24
Time frame: Baseline up to Weeks 22, and 24
DB Phase: Change From Baseline in the Visual Analog Scale (VAS) Score of European Quality of Life (EuroQol) 5-Dimension 5-Level (EQ-5D-5L) Scale Over 24 Weeks
Time frame: Baseline up to Week 24
DB Phase: Change From Baseline in the Health Status Index of the EuroQol 5-Dimension 5-Level (EQ-5D-5L) Scale Over 24 Weeks
Time frame: Baseline up to Week 24
DB Phase: Percentage of Participants With Myasthenia Gravis - Activities of Daily Living (MG-ADL) Score of 0 or 1 Over Time
Time frame: Baseline up to Week 24
DB Phase: Percentage of Participants With Myasthenia Gravis - Activities of Daily Living (MG-ADL) Score of 0 or 1 at Any Time
Time frame: Baseline up to Week 24
DB Phase: Percentage of Participants With Myasthenia Gravis - Activities of Daily Living (MG-ADL) Score of 0 or 1 at 50% of Timepoints
Time frame: Baseline up to Week 24
DB Phase: Percentage of Participants With Myasthenia Gravis - Activities of Daily Living (MG-ADL) Score of 0 or 1 at 75% of Timepoints
Time frame: Baseline up to Week 24
Serum Concentrations of Nipocalimab Over Time
Time frame: DB Phase: Predose and 45 minutes post-dose on Day 1, Weeks 2, 4, 8, 12,16, 20, 24;OL Phase: Predose on Day 1, Weeks 8, 16, 24, 36, 48, 60, 72, 84, and 96
Number of Participants With Antibodies to Nipocalimab (Anti-Drug Antibodies [ADAs] and Neutralizing Antibodies [NAbs])
Time frame: From start of treatment (Day 1) up to 4 years 9 months
Percent Change From Baseline in Total Serum Immunoglobulin G (IgG) Concentrations
Time frame: Baseline up to 4 years 9 months
Change From Baseline in Levels of Autoantibodies Associated With Generalized Myasthenia Gravis (gMG)
Time frame: Baseline up to 4 years 9 months
Change From Baseline in Myasthenia Gravis - Activities of Daily Living (MG-ADL) Score as a Function of IgG
Time frame: Baseline up to 4 years 9 months
Change From Baseline in Quantitative Myasthenia Gravis (QMG) Score as a Function of Immunoglobulin G (IgG)
Time frame: Baseline up to 4 years 9 months
Change From Baseline in Myasthenia Gravis - Activities of Daily Living (MG-ADL) Score as a Response to Percent Change in Autoantibody Levels in Seropositive Participants Treated With Nipocalimab
Time frame: Baseline up to 4 years 9 months
Change From Baseline in QMG Score as a Response to Percent Change in Autoantibody Levels in Seropositive Participants Treated With Nipocalimab
Time frame: Baseline up to 4 years 9 months
Sub Study: Number of Participants With Treatment-Emergent AEs
Time frame: Up to SC Week 8 (Day 57)
Sub Study: Number of Participants With Abnormalities in Vital Signs
Time frame: Up to SC Week 8 (Day 57)
Sub Study: Number of Participants With Abnormalities in Physical Examinations
Time frame: Up to SC Week 8 (Day 57)
Sub Study: Number of Participants With Abnormalities in Laboratory Parameters
Time frame: Up to SC Week 8 (Day 57)
Sub Study: Numeric Pain Rating Scale (NPRS) Assessment With SC Use of Nipocalimab
Time frame: Up to SC Week 8 (Day 57)
Sub Study: Number of Participants With Injection Site-Reactions
Time frame: Up to SC Week 8 (Day 57)
Sub Study: Change From Baseline in MG-ADL Clinician-Reported Outcome Measures up to Week 8 (Day 57)
Time frame: From baseline (pre-first nipocalimab dose on Day 1) up to Week 8 (Day 57)
Sub Study: Change From Baseline in QMG Clinician-Reported Outcome Measures up to Week 8 (Day 57)
Time frame: From baseline (pre-first nipocalimab dose on Day 1) up to Week 8 (Day 57)
Sub Study: Change From Baseline in Myasthenia Gravis Foundation of America (MGFA) Clinician-Reported Measures up to Week 8 (Day 57)
Time frame: From baseline (pre-first nipocalimab dose on Day 1) up to Week 8 (Day 57)
Sub Study: Change From Baseline in C-SSRS Clinician-Reported Outcome Measures up to Week 8 (Day 57)
Time frame: From baseline (pre-first nipocalimab dose on Day 1) up to Week 8 (Day 57)
Sub Study: Change From Baseline in Neuro-QoL Participant-Reported Outcome Measures up to Week 8 (Day 57)
Time frame: From baseline (pre-first nipocalimab dose on Day 1) up to Week 8 (Day 57)
Sub Study: Change From Baseline in Patient Global Impression of Severity (PGIS) Scale Score up to Week 8 (Day 57)
Time frame: From baseline (pre-first nipocalimab dose on Day 1) up to Week 8 (Day 57)
Sub Study: Change From Baseline in Patient Global Impression of Change (PGIC) Scale Score up to Week 8 (Day 57)
Time frame: From baseline (pre-first nipocalimab dose on Day 1) up to Week 8 (Day 57)
Sub Study: Change From Baseline in MG-QoL Participant-Reported Outcome Measures up to Week 8 (Day 57)
Time frame: From baseline (pre-first nipocalimab dose on Day 1) up to Week 8 (Day 57)
Sub Study: Change From Baseline in EQ-5D-5L Participant-Reported Outcome Measures up to Week 8 (Day 57)
Time frame: From baseline (pre-first nipocalimab dose on Day 1) up to Week 8 (Day 57)
Sub Study: Percent Change in Total IgG Levels From Pre-first Nipocalimab Dose on Day 1 up to Week 8 (Day 57)
Time frame: From pre-first nipocalimab dose on Day 1 up to Week 8 (Day 57)
Sub Study: Percent Change in Anti-AChR Autoantibody Titer From Pre-first Nipocalimab Dose on Day 1 up to Week 8 (Day 57)
Time frame: From pre-first nipocalimab dose on Day 1 up to Week 8 (Day 57)
| Milestone | Double Blind (DB) Phase: Placebo | DB Phase: Nipocalimab | OLE Phase: Placebo to Nipocalimab | OLE Phase: Nipocalimab | OLE Phase: Nipocalimab (MOM-M281-004 and MOM-M281-005) |
|---|---|---|---|---|---|
| Started | 99 | 100 | 0 | 0 | 0 |
| Treated | 98 | 98 | 0 | 0 | 0 |
| Completed | 82 | 87 | 0 | 0 | 0 |
| Not completed | 17 | 13 | 0 | 0 | 0 |
| Withdrew: Adverse event | 7 | 5 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 2 | 0 | 0 | 0 |
| Withdrew: Death | 2 | 1 | 0 | 0 | 0 |
| Withdrew: Disease relapse | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Randomized by mistake | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Subject refused further study treatment | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Failure to meet randomization criteria | 0 | 1 | 0 | 0 | 0 |
| Milestone | Double Blind (DB) Phase: Placebo | DB Phase: Nipocalimab | OLE Phase: Placebo to Nipocalimab | OLE Phase: Nipocalimab | OLE Phase: Nipocalimab (MOM-M281-004 and MOM-M281-005) |
|---|---|---|---|---|---|
| Started | 0 | 0 | 88 | 88 | 20 |
| Treated | 0 | 0 | 88 | 88 | 19 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 88 | 88 | 20 |
| Withdrew: Adverse event | 0 | 0 | 5 | 0 | 2 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 5 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 3 | 7 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Ongoing | 0 | 0 | 77 | 74 | 15 |
| Withdrew: Met eligibility criteria but discontinued during the screening period (not treated) | 0 | 0 | 0 | 0 | 1 |
Average change from baseline over multiple timepoints (Weeks 22, 23, and 24) was reported in this outcome measure. The MG-ADL provided a rapid assessment of the participant's MG symptom severity of eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, eyelid droop) rated on a 4-point scale ranging from 0 (normal) to 3 (severe). MG-ADL total score was sum of 8 individual items, which ranging from 0 to 24. A higher score indicated greater symptom severity. Baseline was defined as the average of the screening and Day 1 total scores.
| Score on a scale | Double Blind (DB) Phase: Placebo | DB Phase: Nipocalimab |
|---|---|---|
| Double-blind (DB) Phase: Average Change From Baseline in Myasthenia Gravis - Activities of Daily Living (MG-ADL) Total Score Over Weeks 22, 23, and 24 | -3.25 ± 0.335 | -4.70 ± 0.329 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over DB: All-cause mortality: From screening (Day -28) to Week 24; SAE and other AEs: From Day 1 (Week 0) to Week 24; OLE: From Week 24 (OLE Day 1) up to 2 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double Blind (DB) Phase: Placebo | 2/99 (2%) | 14/98 (14.3%) | 65/98 (66.3%) |
| DB Phase: Nipocalimab | 1/100 (1%) | 9/98 (9.2%) | 69/98 (70.4%) |
| OLE Phase: Placebo to Nipocalimab | 1/88 (1.1%) | 10/88 (11.4%) | 57/88 (64.8%) |
| OLE Phase: Nipocalimab | 1/88 (1.1%) | 16/88 (18.2%) | 59/88 (67%) |
| OLE Phase: Nipocalimab (MOMM281- 004 and MOM-M281-005) | 1/19 (5.3%) | 7/19 (36.8%) | 18/19 (94.7%) |
| Event | Double Blind (DB) Phase: Placebo | DB Phase: Nipocalimab | OLE Phase: Placebo to Nipocalimab | OLE Phase: Nipocalimab | OLE Phase: Nipocalimab (MOMM281- 004 and MOM-M281-005) |
|---|---|---|---|---|---|
| Myasthenia GravisNervous system disorders | 4/98 | 3/98 | 1/88 | 6/88 | 2/19 |
| Atrial FibrillationCardiac disorders | 0/98 | 0/98 | 0/88 | 0/88 | 1/19 |
| Cardio-Respiratory ArrestCardiac disorders | 0/98 | 0/98 | 0/88 | 0/88 | 1/19 |
| Escherichia BacteraemiaInfections and infestations | 0/98 | 0/98 | 0/88 | 0/88 | 1/19 |
| SepsisInfections and infestations | 1/98 | 0/98 | 1/88 | 1/88 | 1/19 |
| Urinary Tract InfectionInfections and infestations | 0/98 | 0/98 | 0/88 | 0/88 | 1/19 |
| Hip FractureInjury, poisoning and procedural complications | 0/98 | 0/98 | 0/88 | 0/88 | 1/19 |
| Spinal FractureInjury, poisoning and procedural complications | 0/98 | 0/98 | 0/88 | 0/88 | 1/19 |
| Myasthenia Gravis CrisisNervous system disorders | 2/98 | 1/98 | 1/88 | 0/88 | 1/19 |
| Major DepressionPsychiatric disorders | 0/98 | 0/98 | 0/88 | 0/88 | 1/19 |
| Event | Double Blind (DB) Phase: Placebo | DB Phase: Nipocalimab | OLE Phase: Placebo to Nipocalimab | OLE Phase: Nipocalimab | OLE Phase: Nipocalimab (MOMM281- 004 and MOM-M281-005) |
|---|---|---|---|---|---|
| Covid-19Infections and infestations | 9/98 | 11/98 | 7/88 | 7/88 | 5/19 |
| Upper Respiratory Tract InfectionInfections and infestations | 8/98 | 6/98 | 9/88 | 9/88 | 5/19 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 3/98 | 5/98 | 2/88 | 4/88 | 4/19 |
| Myasthenia GravisNervous system disorders | 9/98 | 9/98 | 5/88 | 8/88 | 4/19 |
| HeadacheNervous system disorders | 17/98 | 14/98 | 10/88 | 5/88 | 2/19 |
| DiarrhoeaGastrointestinal disorders | 3/98 | 7/98 | 5/88 | 2/88 | 3/19 |
| BronchitisInfections and infestations | 1/98 | 2/98 | 2/88 | 2/88 | 3/19 |
| FallInjury, poisoning and procedural complications | 1/98 | 0/98 | 3/88 | 2/88 | 3/19 |
| NasopharyngitisInfections and infestations | 10/98 | 9/98 | 11/88 | 10/88 | 2/19 |
| Muscle SpasmsMusculoskeletal and connective tissue disorders | 3/98 | 12/98 | 3/88 | 6/88 | 2/19 |
The full analysis set included all randomized participants who received at least 1 dose (partial or complete) of any study intervention in the double-blind phase. The safety analysis set (OL) included all participants who received at least 1 dose (partial or complete) of nipocalimab in the OLE phase
| Age, Continuous(Years) | Double Blind (DB) Phase: Placebo | DB Phase: Nipocalimab | OLE Phase: Nipocalimab (MOM-M281-004 and MOM-M281-005) | Total |
|---|---|---|---|---|
| Mean | 52.7 ± 15.60 | 52.9 ± 15.49 | 52.7 ± 17.69 | 52.8 ± 15.74 |
| Sex: Female, Male(Participants) | Double Blind (DB) Phase: Placebo | DB Phase: Nipocalimab | OLE Phase: Nipocalimab (MOM-M281-004 and MOM-M281-005) | Total |
|---|---|---|---|---|
| Female | 56 | 66 | 10 | 132 |
| Male | 42 | 32 | 9 | 83 |
| Ethnicity (NIH/OMB)(Participants) | Double Blind (DB) Phase: Placebo | DB Phase: Nipocalimab | OLE Phase: Nipocalimab (MOM-M281-004 and MOM-M281-005) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 6 | 10 | 5 | 21 |
| Not Hispanic or Latino | 89 | 87 | 14 | 190 |
| Unknown or Not Reported | 3 | 1 | 0 | 4 |
| Race (NIH/OMB)(Participants) | Double Blind (DB) Phase: Placebo | DB Phase: Nipocalimab | OLE Phase: Nipocalimab (MOM-M281-004 and MOM-M281-005) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 29 | 28 | 0 | 57 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 0 | 2 |
| White | 65 | 66 | 19 | 150 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 2 | 0 | 5 |
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Showing the first 100 of 112 sites across 17 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · innovativemedicine.jnj.com
Ran from Jul 2021 to primary completion in Nov 2023, 28 months.
Results were first posted in Jul 2025, 1 year 8 months after primary completion. A results delay was requested in Oct 2024.
Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 28 months is close to that.
Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nipocalimab
Janssen Research & Development, LLC →